Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1596

Shown on this page

Current sort

Stored official records

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Matching Placebo to JNJ-77242113, Matching Placebo to Ustekinumab, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Birmingham, Alabama • Encinitas, California • Encino, California + 41 more

Conditions: Leukemia, Myeloid, Acute
Interventions: Azacitidine (AZA), Bleximenib, Placebo, Venetoclax (VEN); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 59
States / cities: Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 43 more

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil, Amivantamab, Bevacizumab, Cetuximab, Irinotecan, Leucovorin calcium/Levoleucovorin; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 71
States / cities: Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil, Amivantamab, Cetuximab, Irinotecan Hydrochloride, Leucovorin calcium/Levoleucovorin, Oxaliplatin; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 81
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more

Conditions: Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Systemic Anaplastic Large Cell Lymphoma
Interventions: Belinostat, Pralatrexate, Soquelitinib; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Duarte, California • Irvine, California • San Francisco, California + 19 more

Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions: Docetaxel, Gemcitabine, Nadofaragene Firadenovec, Pembrolizumab; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 40
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Neoplasms
Interventions: Cetrelimab, JNJ-87704916, Standard of Care PD(L)-1; Drug
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Elotuzumab, Pomalidomide, Talquetamab, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 49
States / cities: Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: Dementia, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder
Interventions: Cognitive Training, Daily Exercise, Enhanced Social Support, Intra-operative Standard of Care, Meditation, Personalized CPC Prehabilitation, Pre-operative Standard of Care, Proactive Bundle Interventions; Behavioral · Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Castrate-sensitive Prostate Cancer
Interventions: Androgen-deprivation Therapy (ADT), Apalutamide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Bladder Cancer
Interventions: BCG Vesiculture, Cetrelimab, TAR-200; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Stored official records

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Prediction and Prevention of Postoperative Mortality and Morbidity

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

About this UPMC (University of Pittsburgh) institution page